中國綠地博大綠澤(01253.HK)年度純利升20.49%至7138.3萬元
格隆匯4月1日丨中國綠地博大綠澤(01253.HK)公佈,截至2019年12月31日止年度,實現收益9.49億元人民幣(單位下同),同比增長6.69%;毛利2.11億元,同比減少5.20%,毛利率22.3%;母公司擁有人應占純利7138.3萬元,同比增長20.49%,純利率7.5%;基本每股盈利0.02元,不派息。
業績上升,主要得益於集團的審時度勢,積極盤活存量項目、加大在手項目的回款力度、嚴控項目質量;同時在考核新項目的可行性上,加強決策控制流程,選擇優勢合作方做好存量項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.